Brand Reference: Dostinex
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cabergoline RxNorm Concept ID | 10391 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $4.1200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $176.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $18.60 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $24.00 / mo | 15 Zero-PHI Verified Patient Logs |
Ergoline selective D2-dopamine receptor agonist on anterior pituitary lactotrophs that suppresses adenylyl cyclase and prolactin exocytosis for up to 14 days per dose—shrinking prolactinomas and restoring prolactin-suppressed GnRH/testosterone and male refractory period.
For self-pay patients filling Cabergoline (NDC 00378-0681-44), direct wholesale and telehealth fulfillment drops monthly spend from $176.00 retail to $18.60 (89% savings against a $4.1200 CMS pharmacy acquisition baseline).
Clinical clearance of Cabergoline (Long-Acting Lactotroph Dopamine D2-Receptor Agonist) relies on hepatic non-cyp amide hydrolysis; biliary fecal excretion with a 63–69 hours half-life; patients absorbing at ~60% oral (unaffected by food) bioavailability typically observe target onset around 3 hours prolactin drop; 2–4 weeks normalization.
FDA clinical labeling for Cabergoline restricts administration in pre-existing cardiac valvular fibrosis or thickening (5-ht2b agonist at parkinsonian doses); uncontrolled preeclampsia hypertension across 0.25 mg PO twice weekly, 0.5 mg PO twice weekly, with self-reported patient tracking dominated by postural lightheadedness (13% of reports), nausea (11% of reports), nasal stuffiness (6% of reports).
Across 15 verified cash-pay logs, Cabergoline achieves a 89.70% Worth-It rating with out-of-pocket spend averaging $24.00/mo versus $176.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.25 mg PO twice weekly for Cabergoline; monthly out-of-pocket dropped to $16.37 compared with $176.00 retail.
Completed 10 weeks on Cabergoline (0.5 mg PO twice weekly). Zero notable side effects on steady dosing.
Consistent biomarker response on 0.25 mg PO twice weekly Cabergoline sourced via TeleMed ($21.58/mo cash pay without insurance prior authorization).